Retrospective WGS study
Research type
Research Study
Full title
Assessing the clinical benefits of whole genome sequencing for children with neoplasms
IRAS ID
319310
Contact name
Sam Behjati
Contact email
Duration of Study in the UK
2 years, 6 months, 31 days
Research summary
The NHSE-commissioned whole genome sequencing programme went live at the end of 2020. It remains as yet unproven, whether this whole genome sequencing programme for children with cancer can deliver tangible benefits in real-time. There is an urgent need, therefore, to assess whether children with tumours who are receiving NHS whole genome sequencing are actually benefiting from this additional assay. This is a retrospective case series. The principal methodology is that of reviewing clinical notes to assess whether children with tumours have benefited from NHSE whole genome sequencing. Apart from the contribution of our work to the scientific literature, this research will inform government on the potential benefits, or lack thereof, of the live NHSE whole genome programme and has the potential to influence policy on whether this programme should be continued.
REC name
Wales REC 5
REC reference
22/WA/0281
Date of REC Opinion
22 Sep 2022
REC opinion
Further Information Favourable Opinion